Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024)
Climb Bio (CLYM) posted Total Non-Current Liabilities of $5.3 million for Q4 2024, up 55.01% on a QoQ basis from $3.4 million in Q3 2024, and up 86.31% year-over-year from $2.8 million in Q1 2024.
Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends
Climb Bio's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $5.3 million for Q4 2024.
- Quarterly Total Non-Current Liabilities rose 86.31% year-over-year to $5.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.3 million (up 86.31% YoY) and the FY2024 annual result came in at $5.3 million, up 86.31% from the prior year.
- Total Non-Current Liabilities was $5.3 million for Q4 2024 at Climb Bio, up from $3.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $7.9 million in Q2 2022 and bottomed at $2.5 million in Q4 2020.
- A 5-year average of $4.8 million and a median of $4.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 140.09% — and 2023, when it tumbled 54.63%.
- Climb Bio's Total Non-Current Liabilities stood at $2.5 million in 2020, then jumped by 140.09% to $6.0 million in 2021, then increased by 4.08% to $6.3 million in 2022, then tumbled by 54.63% to $2.8 million in 2023, then jumped by 86.31% to $5.3 million in 2024.
- Business Quant data shows CLYM's Total Non-Current Liabilities at $5.3 million in Q4 2024, $3.4 million in Q3 2024, and $3.7 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.31 Mn |
| Sep 30, 2024 | 3.42 Mn |
| Jun 30, 2024 | 3.74 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 2.85 Mn |
| Sep 30, 2023 | 2.96 Mn |
| Jun 30, 2023 | 3.72 Mn |
| Mar 31, 2023 | 5.14 Mn |
| Dec 31, 2022 | 6.28 Mn |
| Sep 30, 2022 | 6.50 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 7.28 Mn |
| Dec 31, 2021 | 6.03 Mn |
| Dec 31, 2020 | 2.51 Mn |